Swiss researchers from Zurich and Basel have discovered that resistance in intestinal bacteria can spread even if no antibiotic is used. Their results are…
WHO has published target product profiles for diagnostics against antibacterial resistance identified as priorities. Until 29th September a public consultation process is open. Based…
Erin Duffy, former CSO of US biotech company Melinta Therapeutics, replaces Karen Gallant as CARB-X‘s Chief of Research and Development. Erin Duffy will be…
CARB-X has recently funded several vaccines projects to fight AMR-related infections developed by US-based SutroVax and Swiss Vaxxilon AG. In early September, CARB-X has…
The WHO has developed several draft target products profiles (TPPs) and is seeking feedback from AMR stakeholders until 29th September 2019. The global increase…
Nabriva Therapeutics plc has got the go from the FDA to market its pleuromutilin antibiotic Xenleta (lefamulin), a protein synthesis blocker with new mode-of-action…
Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents today: Gram-Negative Antibacterials NOW (“GNA NOW”).…